CA3222144A1 - Substituted indole compounds and methods of use thereof - Google Patents
Substituted indole compounds and methods of use thereof Download PDFInfo
- Publication number
- CA3222144A1 CA3222144A1 CA3222144A CA3222144A CA3222144A1 CA 3222144 A1 CA3222144 A1 CA 3222144A1 CA 3222144 A CA3222144 A CA 3222144A CA 3222144 A CA3222144 A CA 3222144A CA 3222144 A1 CA3222144 A1 CA 3222144A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- heterocyclyl
- methoxy
- cycloalkyl
- 3a1ky1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163196339P | 2021-06-03 | 2021-06-03 | |
| US63/196,339 | 2021-06-03 | ||
| US202163290019P | 2021-12-15 | 2021-12-15 | |
| US63/290,019 | 2021-12-15 | ||
| US202263346120P | 2022-05-26 | 2022-05-26 | |
| US63/346,120 | 2022-05-26 | ||
| PCT/US2022/032042 WO2022256586A2 (en) | 2021-06-03 | 2022-06-03 | Substituted indole compounds and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3222144A1 true CA3222144A1 (en) | 2022-12-08 |
Family
ID=84323595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3222144A Pending CA3222144A1 (en) | 2021-06-03 | 2022-06-03 | Substituted indole compounds and methods of use thereof |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20240287034A1 (enExample) |
| EP (1) | EP4346812A4 (enExample) |
| JP (1) | JP7895996B2 (enExample) |
| KR (1) | KR20240017004A (enExample) |
| CN (1) | CN120081822A (enExample) |
| AU (1) | AU2022283903A1 (enExample) |
| BR (1) | BR112023025235A2 (enExample) |
| CA (1) | CA3222144A1 (enExample) |
| CL (1) | CL2023003591A1 (enExample) |
| CO (1) | CO2023016557A2 (enExample) |
| CR (1) | CR20230564A (enExample) |
| DO (1) | DOP2023000263A (enExample) |
| EC (1) | ECSP23090260A (enExample) |
| IL (1) | IL308835A (enExample) |
| JO (1) | JOP20230315A1 (enExample) |
| MX (1) | MX2023014274A (enExample) |
| PE (1) | PE20250114A1 (enExample) |
| PH (1) | PH12023553130A1 (enExample) |
| WO (1) | WO2022256586A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230049115A (ko) * | 2020-08-07 | 2023-04-12 | 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 | 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도 |
| US20240109861A1 (en) * | 2020-12-30 | 2024-04-04 | Medshine Discovery Inc. | Series of piperidine-substituted benzoic acid compounds, and use thereof |
| WO2023278698A1 (en) * | 2021-06-30 | 2023-01-05 | Apellis Pharmaceuticals, Inc. | Complement inhibition |
| CN118043314A (zh) | 2021-08-18 | 2024-05-14 | 西藏海思科制药有限公司 | 一种苯并氮杂芳环衍生物及其在医药上的应用 |
| AU2022376760A1 (en) * | 2021-10-27 | 2024-05-02 | Hansoh Bio Llc | Piperidinyl indole derivatives, preparation methods and medicinal uses thereof |
| PE20242005A1 (es) * | 2022-01-24 | 2024-10-03 | Novartis Ag | Derivados espirociclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos |
| WO2023237012A1 (zh) * | 2022-06-07 | 2023-12-14 | 正大天晴药业集团股份有限公司 | 双环取代的芳香羧酸类氘代化合物 |
| CN119698414A (zh) * | 2022-06-20 | 2025-03-25 | 深圳信立泰药业股份有限公司 | 一种吲哚-苯基哌啶化合物及其制备方法与应用 |
| CN119546585A (zh) * | 2022-06-23 | 2025-02-28 | 上海济煜医药科技有限公司 | 吲哚化合物的制备、应用及用途 |
| TW202423426A (zh) * | 2022-08-31 | 2024-06-16 | 美商奇努克醫療股份有限公司 | 經取代之吲哚化合物及其使用方法 |
| JP2025530222A (ja) * | 2022-09-10 | 2025-09-11 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | ２－置換ピペリジン誘導体、その製造方法及び医薬的用途 |
| US20260159497A1 (en) * | 2022-11-14 | 2026-06-11 | Novartis Pharma Ag | Solid forms of a complement factor b inhibitor |
| CN120303261A (zh) * | 2022-11-29 | 2025-07-11 | 上海济煜医药科技有限公司 | 苯并螺环吲哚化合物的制备、应用及用途 |
| WO2024148274A1 (en) * | 2023-01-05 | 2024-07-11 | Apellis Pharmaceuticals, Inc. | Complement inhibition |
| EP4650351A1 (en) * | 2023-01-09 | 2025-11-19 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Inhibitor of complement factor b |
| JP2026506078A (ja) * | 2023-02-16 | 2026-02-20 | ハイスーク ファーマシューティカル グループ カンパニー リミテッド | ベンゾアザ芳香環誘導体の塩、結晶形及びその医薬的応用 |
| TW202434240A (zh) * | 2023-02-22 | 2024-09-01 | 大陸商西藏海思科製藥有限公司 | 苯並氮雜芳環衍生物的藥物組合物及其在醫藥上的應用 |
| AU2024261191A1 (en) * | 2023-04-27 | 2025-11-06 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Salt of piperidylindole compound and preparation method therefor |
| EP4739390A1 (en) | 2023-07-04 | 2026-05-13 | Sitala Bio Ltd | 2-(1h-indol-4-yl)methyl)2h-indazole derivatives as factor b inhibitors |
| CN121752557A (zh) | 2023-07-04 | 2026-03-27 | 希塔拉生物有限公司 | 2-(1h-吲哚-4-基)甲基)-异吲哚啉衍生物作为因子b抑制剂 |
| WO2025008516A2 (en) | 2023-07-06 | 2025-01-09 | Sitala Bio Ltd | Novel compounds |
| WO2025008517A1 (en) | 2023-07-06 | 2025-01-09 | Sitala Bio Ltd | Indole derivatives with factor b inhibitory activity |
| CN119371402A (zh) * | 2023-07-26 | 2025-01-28 | 上海美悦生物科技发展有限公司 | 螺环烯基类或氮杂烯基类化合物及其药物组合物、制备方法和用途 |
| TW202517258A (zh) * | 2023-09-20 | 2025-05-01 | 大陸商上海美悦生物科技發展有限公司 | 雜環化合物在製備預防和／或治療腎臟疾病的藥物中的用途 |
| CN122396492A (zh) * | 2023-12-05 | 2026-07-14 | 西藏海思科制药有限公司 | 苯并氮杂芳环衍生物在治疗补体因子b介导的疾病中的用途 |
| WO2025172535A1 (en) | 2024-02-15 | 2025-08-21 | Sitala Bio Ltd | Indole and benzimidazole compounds as factor b inhibitors |
| WO2025256647A1 (zh) * | 2024-06-14 | 2025-12-18 | 润尔眼科药物（广州）有限公司 | 化合物及其医药用途 |
| WO2026008073A1 (zh) * | 2024-07-05 | 2026-01-08 | 南京正大天晴制药有限公司 | 补体因子b抑制剂的剂量组合物 |
| WO2026069246A1 (en) * | 2024-09-30 | 2026-04-02 | Novartis Ag | Complement factor b inhibitors and uses thereof |
| CN121949280A (zh) * | 2024-10-31 | 2026-05-01 | 甫康（上海）健康科技有限责任公司 | 一种多取代吲哚类化合物及其制备方法和用途 |
| GB202500206D0 (en) | 2025-01-08 | 2025-02-19 | Sitala Bio Ltd | Novel compounds |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201406973PA (en) * | 2012-05-04 | 2014-12-30 | Novartis Ag | Complement pathway modulators and uses thereof |
| CN104619698B (zh) * | 2012-06-28 | 2016-08-31 | 诺华股份有限公司 | 吡咯烷衍生物及其作为补体途径调节剂的用途 |
| JO3425B1 (ar) * | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| MX2018016046A (es) * | 2016-06-27 | 2019-05-02 | Achillion Pharmaceuticals Inc | Quinazolina y compuestos indol para tratar trastornos medicos. |
| KR20230049115A (ko) | 2020-08-07 | 2023-04-12 | 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 | 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도 |
| WO2022254362A1 (en) | 2021-06-03 | 2022-12-08 | Novartis Ag | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof |
| CN117412955A (zh) | 2021-06-03 | 2024-01-16 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| KR20240024926A (ko) | 2021-06-24 | 2024-02-26 | 신젠타 크롭 프로텍션 아게 | 살충제로서의 2-[3-[1[(퀴나졸린-4-일)아미노]에틸]피라진-2-일]티아졸-5-카르보니트릴 유도체 및 유사한 화합물 |
| WO2023283256A1 (en) | 2021-07-09 | 2023-01-12 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| MX2024001269A (es) | 2021-07-26 | 2024-04-23 | Harvard College | Inhibidores de rock2 y sus usos. |
| AU2022376760A1 (en) * | 2021-10-27 | 2024-05-02 | Hansoh Bio Llc | Piperidinyl indole derivatives, preparation methods and medicinal uses thereof |
| AR127922A1 (es) | 2021-12-15 | 2024-03-13 | Syngenta Crop Protection Ag | Derivados heterocíclicos bicíclicos microbiocidas |
| US20250326757A1 (en) | 2022-05-26 | 2025-10-23 | Astrazeneca Ab | Solid forms of heterocyclylamides as irak4 inhibitors |
-
2022
- 2022-06-03 PE PE2023003178A patent/PE20250114A1/es unknown
- 2022-06-03 KR KR1020237045081A patent/KR20240017004A/ko active Pending
- 2022-06-03 PH PH1/2023/553130A patent/PH12023553130A1/en unknown
- 2022-06-03 JP JP2023574119A patent/JP7895996B2/ja active Active
- 2022-06-03 CA CA3222144A patent/CA3222144A1/en active Pending
- 2022-06-03 IL IL308835A patent/IL308835A/en unknown
- 2022-06-03 BR BR112023025235A patent/BR112023025235A2/pt unknown
- 2022-06-03 WO PCT/US2022/032042 patent/WO2022256586A2/en not_active Ceased
- 2022-06-03 AU AU2022283903A patent/AU2022283903A1/en active Pending
- 2022-06-03 CR CR20230564A patent/CR20230564A/es unknown
- 2022-06-03 MX MX2023014274A patent/MX2023014274A/es unknown
- 2022-06-03 US US18/566,259 patent/US20240287034A1/en active Pending
- 2022-06-03 CN CN202510248844.6A patent/CN120081822A/zh active Pending
- 2022-06-03 EP EP22816892.8A patent/EP4346812A4/en active Pending
-
2023
- 2023-11-30 EC ECSENADI202390260A patent/ECSP23090260A/es unknown
- 2023-11-30 CL CL2023003591A patent/CL2023003591A1/es unknown
- 2023-11-30 DO DO2023000263A patent/DOP2023000263A/es unknown
- 2023-11-30 CO CONC2023/0016557A patent/CO2023016557A2/es unknown
- 2023-11-30 JO JOJO/P/2023/0315A patent/JOP20230315A1/ar unknown
-
2025
- 2025-05-30 US US19/223,498 patent/US12617774B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023025235A2 (pt) | 2024-02-27 |
| AU2022283903A1 (en) | 2023-11-30 |
| IL308835A (en) | 2024-01-01 |
| CN120081822A (zh) | 2025-06-03 |
| JP2024521878A (ja) | 2024-06-04 |
| JP7895996B2 (ja) | 2026-07-28 |
| CR20230564A (es) | 2024-02-27 |
| US20240287034A1 (en) | 2024-08-29 |
| WO2022256586A3 (en) | 2023-01-12 |
| PH12023553130A1 (en) | 2024-03-11 |
| ECSP23090260A (es) | 2024-02-29 |
| EP4346812A4 (en) | 2025-04-09 |
| DOP2023000263A (es) | 2024-02-29 |
| MX2023014274A (es) | 2024-04-22 |
| WO2022256586A2 (en) | 2022-12-08 |
| PE20250114A1 (es) | 2025-01-16 |
| JOP20230315A1 (ar) | 2023-11-30 |
| CO2023016557A2 (es) | 2024-02-26 |
| CL2023003591A1 (es) | 2024-06-28 |
| US12617774B2 (en) | 2026-05-05 |
| KR20240017004A (ko) | 2024-02-06 |
| US20250289804A1 (en) | 2025-09-18 |
| EP4346812A2 (en) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12617774B2 (en) | Substituted indole compounds and methods of use thereof | |
| AU2020262221B2 (en) | 4H-pyrrolo(3,2-c)pyridin-4-one compounds | |
| AU2022329230A1 (en) | Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine | |
| JP7177825B2 (ja) | スピロ環化合物並びにその作製及び使用方法 | |
| CA3217417A1 (en) | Compounds for targeting degradation of bruton's tyrosine kinase | |
| US9834541B2 (en) | 2-aminopyridine compounds | |
| KR20180021860A (ko) | Magl 억제제로서의 1,1,1-트리플루오로-3-히드록시프로판-2-일 카르바메이트 유도체 및 1,1,1-트리플루오로-4-히드록시부탄-2-일 카르바메이트 유도체 | |
| WO2024049977A1 (en) | Substituted indole compounds and methods of use thereof | |
| CN103748087A (zh) | 吲唑和吡咯并吡啶衍生物和其药学用途 | |
| CN117500499A (zh) | 经取代的吲哚化合物及其使用方法 | |
| TW202404952A (zh) | Qpctl及qpct之抑制劑 | |
| JP7661533B2 (ja) | Ｎｒｆ２活性化作用を有する含窒素複素環化合物 | |
| KR20230051500A (ko) | Alk5 억제제로서 피리다진일 아미노 유도체 | |
| JP2025060769A (ja) | アミノアジンアミド | |
| JP2014133739A (ja) | インダゾール誘導体またはピロロピリジン誘導体からなる医薬 | |
| WO2024260929A1 (en) | Trem2 agonists | |
| KR20240013134A (ko) | 시그마 리간드로서 피리딘-술폰아미드 유도체 | |
| US20240239781A1 (en) | 1h-pyrazole derivatives as sigma ligands | |
| TW202333664A (zh) | 新穎雜環化合物 | |
| KR20240021758A (ko) | 시그마 리간드로서 신규 피라졸로[1,5-a]피리미딘 유도체 | |
| EA052249B1 (ru) | Замещенные индольные соединения и способы их применения | |
| JP2024513117A (ja) | シグマリガンドとしての新規（ホモ）ピペリジニル複素環 | |
| JP6337092B2 (ja) | 三環式トリアゾール系化合物 | |
| WO2026008604A1 (en) | Compounds and pharmaceutical compositions thereof for the treatment of proliferative diseases | |
| WO2026093401A1 (en) | Macrocyclic compounds and pharmaceutical compositions thereof for the treatment of proliferative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20241212 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241212 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241226 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241226 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241226 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R125 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMMON REPRESENTATIVE APPOINTED Effective date: 20250305 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250305 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260519 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260519 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260601 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260601 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260601 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260703 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260703 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260703 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260703 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260703 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260710 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260728 |